Anika Therapeutics vs Si-Bone
ANIK and SIBN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIK and SIBN compare
Si-Bone is the larger company, worth 6.1 times as much as Anika Therapeutics ($1.0B against $173M).
Si-Bone grew revenue faster over the last twelve months (15.3% versus 5.3% for Anika Therapeutics).
Anika Therapeutics keeps more of each dollar of sales as profit, with a net margin of −3.1% compared with −6.9% at Si-Bone.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIK | SIBN |
|---|---|---|
| Size and price | ||
| Market cap | $173M | $1.0B |
| Share price | $12.92 | $23.41 |
| Change, 1 year | 27.9% | 35.6% |
| Change, 5 years | −67.4% | 16.9% |
| Beta (5Y) | 1.05 | 0.29 |
| Employees | 235 | 376 |
| StockData Score | ||
| Total score | 11 | 11 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 4 (better) |
| Performance score | 3 | 3 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× (better) | 4.9× |
| P/B | 1.3× (better) | 5.8× |
| EV/EBITDA | 269× | – |
| P/FCF | 308× | – |
| FCF yield | 0.33% (better) | −0.42% |
| Fair value | – | $16.27 |
| Margin of safety | – | −43.9% |
| Growth | ||
| Revenue growth (TTM) | 5.3% | 15.3% (better) |
| Revenue growth, 5Y average | −2.9% | 22.3% (better) |
| Profitability | ||
| Gross margin | 62.2% | 79.5% (better) |
| Operating margin | −4.2% (better) | −8.3% |
| Net margin | −3.1% (better) | −6.9% |
| FCF margin | 0.47% (better) | −2.1% |
| Return on equity | −2.7% (better) | −8.3% |
| Return on invested capital | −4.8% (better) | −19.6% |
| Financial health | ||
| Debt / equity | 0.00 | 0.20 (better) |
| Interest coverage | – | −7.1× |
| Current ratio | 4.48 | 9.15 (better) |
| Altman Z-score | 3.77 | 8.47 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | 8.7% | – |
| Shareholder yield | 8.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 91.9% | 108% |
| Held by insiders | 16.9% | 3.7% |
| Insider net buying, 12 months | $264K (better) | −$14.6M |
| Short interest, % of float | 2.9% | 10.5% |
Go deeper
- ANIK stock overview
- ANIK income statement
- ANIK valuation and score
- SIBN stock overview
- SIBN income statement
- SIBN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.